Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 September 2022 - 6:32AM
Edgar (US Regulatory)
Akari Therapeutics Plc0001541157--12-312022Q2false2022-06-3000015411572022-01-012022-06-300001541157aktx:SeriesWarrantsMemberus-gaap:SubsequentEventMemberaktx:RegisteredDirectOfferingMember2022-09-120001541157aktx:SeriesBWarrantsMemberus-gaap:SubsequentEventMemberaktx:RegisteredDirectOfferingMember2022-09-120001541157aktx:MarchTwoThousandAndTwentyTwentyTwoWarrantsMember2022-06-300001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMember2022-06-300001541157aktx:DecemberTwoThousandAndTwentyTwentyOneWarrantsMember2022-06-300001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-07-160001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-07-160001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberaktx:MeasurementInputStandardDeviationRateMember2021-07-160001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberaktx:MeasurementInputRequiredRateOfReturnOnEquityMember2021-07-160001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberaktx:MeasurementInputPeriodRiskFreeInterestRateMember2021-07-160001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMemberaktx:MeasurementInputAnnualTurnoverRateMember2021-07-160001541157aktx:MarchTwoThousandAndTwentyTwentyTwoWarrantsMember2022-03-100001541157aktx:DecemberTwoThousandAndTwentyTwentyOneWarrantsMember2022-01-040001541157aktx:JulyTwoThousandAndTwentyTwentyOneWarrantsMember2021-07-160001541157aktx:EmployeesAndDirectorMember2022-04-012022-06-300001541157aktx:EmployeesAndDirectorMember2022-01-012022-06-300001541157aktx:EmployeesAndDirectorMember2021-04-012021-06-300001541157aktx:EmployeesAndDirectorMember2021-01-012021-06-300001541157us-gaap:CommonStockMember2022-01-012022-03-3100015411572021-07-072021-07-070001541157us-gaap:CommonStockMember2021-04-012021-06-300001541157aktx:AspireCapitalFundLLCMember2020-01-012020-06-300001541157us-gaap:RetainedEarningsMember2022-06-300001541157us-gaap:CapitalUnitsMember2022-06-300001541157us-gaap:AdditionalPaidInCapitalMember2022-06-300001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001541157us-gaap:RetainedEarningsMember2022-03-310001541157us-gaap:CapitalUnitsMember2022-03-310001541157us-gaap:AdditionalPaidInCapitalMember2022-03-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015411572022-03-310001541157us-gaap:RetainedEarningsMember2021-12-310001541157us-gaap:CapitalUnitsMember2021-12-310001541157us-gaap:AdditionalPaidInCapitalMember2021-12-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001541157us-gaap:RetainedEarningsMember2021-06-300001541157us-gaap:CapitalUnitsMember2021-06-300001541157us-gaap:AdditionalPaidInCapitalMember2021-06-300001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001541157us-gaap:RetainedEarningsMember2021-03-310001541157us-gaap:CapitalUnitsMember2021-03-310001541157us-gaap:AdditionalPaidInCapitalMember2021-03-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100015411572021-03-310001541157us-gaap:RetainedEarningsMember2020-12-310001541157us-gaap:CapitalUnitsMember2020-12-310001541157us-gaap:AdditionalPaidInCapitalMember2020-12-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001541157us-gaap:CommonStockMember2022-06-300001541157us-gaap:CommonStockMember2022-03-310001541157us-gaap:CommonStockMember2021-12-310001541157us-gaap:CommonStockMember2021-06-300001541157us-gaap:CommonStockMember2021-03-310001541157us-gaap:CommonStockMember2020-12-310001541157aktx:AspireCapitalFundLLCMemberdei:AdrMember2021-06-300001541157srt:MinimumMemberaktx:ExercisePriceRangeThreeMember2022-01-012022-06-300001541157srt:MinimumMemberaktx:ExercisePriceRangeFourMember2022-01-012022-06-300001541157srt:MaximumMemberaktx:ExercisePriceRangeThreeMember2022-01-012022-06-300001541157srt:MaximumMemberaktx:ExercisePriceRangeFourMember2022-01-012022-06-300001541157aktx:ExercisePriceRangeOneMember2022-01-012022-06-300001541157aktx:ExercisePriceRangeOneMember2022-06-300001541157aktx:ExercisePriceRangeTwoMember2022-01-012022-06-300001541157aktx:ExercisePriceRangeThreeMember2022-01-012022-06-300001541157aktx:ExercisePriceRangeFourMember2022-01-012022-06-300001541157aktx:ExercisePriceRangeTwoMember2022-06-300001541157aktx:ExercisePriceRangeThreeMember2022-06-300001541157aktx:ExercisePriceRangeFourMember2022-06-300001541157srt:MinimumMember2022-01-012022-06-300001541157srt:MaximumMember2022-01-012022-06-3000015411572022-03-102022-03-1000015411572022-01-042022-01-040001541157aktx:NewEquityIncentivePlanMember2022-01-012022-06-300001541157us-gaap:RestrictedStockUnitsRSUMember2022-06-300001541157srt:MinimumMemberaktx:NewEquityIncentivePlanMember2022-01-012022-06-300001541157srt:MaximumMemberaktx:NewEquityIncentivePlanMember2022-01-012022-06-300001541157us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001541157dei:AdrMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2022-09-120001541157aktx:RegisteredDirectOfferingMember2021-12-290001541157aktx:TwoThousandAndTwentyPurchaseAgreementMember2021-07-070001541157aktx:LaboratoryTestingServicesMember2022-04-012022-06-300001541157aktx:ConsultingServiceMember2022-04-012022-06-300001541157aktx:LaboratoryTestingServicesMember2022-01-012022-06-300001541157aktx:ConsultingServiceMember2022-01-012022-06-300001541157aktx:LaboratoryTestingServicesMember2021-04-012021-06-300001541157aktx:ConsultingServiceMember2021-04-012021-06-300001541157aktx:LaboratoryTestingServicesMember2021-01-012021-06-300001541157aktx:ConsultingServiceMember2021-01-012021-06-300001541157us-gaap:OfficeEquipmentMember2022-01-012022-06-300001541157us-gaap:ComputerEquipmentMember2022-01-012022-06-300001541157us-gaap:OfficeEquipmentMember2022-06-300001541157us-gaap:ComputerEquipmentMember2022-06-300001541157us-gaap:OfficeEquipmentMember2020-12-310001541157us-gaap:ComputerEquipmentMember2020-12-310001541157aktx:RegisteredDirectOfferingMember2022-03-102022-03-100001541157aktx:RegisteredDirectOfferingMember2021-12-292021-12-290001541157aktx:TwoThousandAndTwentyPurchaseAgreementMember2021-07-072021-07-070001541157aktx:AspireCapitalFundLLCMember2021-01-012021-12-310001541157aktx:AspireCapitalFundLLCMemberdei:AdrMember2020-06-012020-06-300001541157aktx:AspireCapitalFundLLCMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2020-01-012020-12-310001541157aktx:AspireCapitalFundLLCMember2022-01-012022-06-300001541157aktx:PlacementAgentWarrantsMemberus-gaap:SubsequentEventMemberaktx:RegisteredDirectOfferingMember2022-09-122022-09-120001541157aktx:PlacementAgentWarrantsMemberaktx:RegisteredDirectOfferingMember2022-03-102022-03-100001541157aktx:PlacementAgentWarrantsMember2022-03-102022-03-100001541157aktx:PlacementAgentWarrantsMemberaktx:RegisteredDirectOfferingMember2022-01-042022-01-040001541157aktx:DoctorsLaboratoryMember2022-04-012022-06-300001541157aktx:DoctorsLaboratoryMember2022-01-012022-06-300001541157aktx:DoctorsLaboratoryMember2021-04-012021-06-300001541157aktx:DoctorsLaboratoryMember2021-01-012021-06-300001541157aktx:AspireCapitalFundLLCMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2022-01-012022-06-300001541157aktx:NonEmployeeMember2022-01-012022-06-300001541157aktx:NonEmployeeMember2022-06-300001541157aktx:LaboratoryTestingServicesMember2022-06-300001541157aktx:LaboratoryTestingServicesMember2021-06-300001541157us-gaap:RetainedEarningsMember2022-04-012022-06-300001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001541157us-gaap:RetainedEarningsMember2022-01-012022-03-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001541157us-gaap:RetainedEarningsMember2021-04-012021-06-300001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001541157us-gaap:RetainedEarningsMember2021-01-012021-03-310001541157us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001541157aktx:PlacementWarrants2020Member2021-12-310001541157aktx:PlacementWarrants2019Member2021-12-310001541157aktx:July2021PlacementAgentWarrantsMember2021-12-310001541157aktx:InvestorWarrants2020Member2021-12-310001541157aktx:InvestorWarrants2019Member2021-12-310001541157aktx:PlacementWarrants2020Member2020-12-310001541157aktx:PlacementWarrants2019Member2020-12-310001541157aktx:InvestorWarrants2020Member2020-12-310001541157aktx:InvestorWarrants2019Member2020-12-310001541157aktx:SeriesWarrantsMemberdei:AdrMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2022-09-120001541157aktx:SeriesBWarrantsMemberdei:AdrMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2022-09-120001541157us-gaap:PrivatePlacementMember2022-06-300001541157aktx:RegisteredDirectOfferingMember2022-06-300001541157aktx:AspireCapitalFundLLCMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2022-03-100001541157aktx:PaulsonWarrantsMemberus-gaap:PrivatePlacementMember2021-12-290001541157aktx:InvestorWarrantsMemberus-gaap:SubsequentEventMemberaktx:RegisteredDirectOfferingMember2022-09-120001541157aktx:PlacementWarrants2020Member2022-06-300001541157aktx:PlacementWarrants2019Member2022-06-300001541157aktx:March2022PlacementAgentWarrantsMember2022-06-300001541157aktx:March2022InvestorWarrantsMember2022-06-300001541157aktx:July2021PlacementAgentWarrantsMember2022-06-300001541157aktx:InvestorWarrants2020Member2022-06-300001541157aktx:InvestorWarrants2019Member2022-06-300001541157aktx:December2021PlacementAgentWarrantsMember2022-06-300001541157aktx:December2021InvestorWarrantsMember2022-06-300001541157aktx:PlacementAgentWarrantsMemberaktx:RegisteredDirectOfferingMember2022-03-100001541157aktx:InvestorWarrantsMemberaktx:RegisteredDirectOfferingMember2022-03-100001541157aktx:PlacementAgentWarrantsMemberaktx:RegisteredDirectOfferingMember2022-01-040001541157aktx:InvestorWarrantsMemberus-gaap:PrivatePlacementMember2021-12-290001541157aktx:PlacementAgentWarrantsMemberus-gaap:PrivatePlacementMember2021-07-310001541157aktx:InvestorWarrantsMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2021-07-1600015411572021-06-300001541157us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001541157us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001541157aktx:WarrantsEquityClassifiedMember2022-01-012022-06-300001541157us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001541157aktx:WarrantsEquityClassifiedMember2021-01-012021-06-300001541157us-gaap:PatentsMember2022-04-012022-06-300001541157us-gaap:PatentsMember2022-01-012022-06-300001541157us-gaap:PatentsMember2021-04-012021-06-300001541157us-gaap:PatentsMember2021-01-012021-06-300001541157us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001541157us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015411572022-01-012022-03-310001541157us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001541157us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100015411572021-01-012021-03-3100015411572020-12-310001541157us-gaap:PrivatePlacementMember2021-07-012021-07-3100015411572021-07-162021-07-160001541157aktx:TwoThousandAndTwentyPurchaseAgreementMemberdei:AdrMember2022-01-012022-06-300001541157dei:AdrMemberus-gaap:SubsequentEventMemberaktx:RegisteredDirectOfferingMember2022-09-122022-09-120001541157aktx:AspireCapitalFundLLCMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2022-06-300001541157aktx:AspireCapitalFundLLCMember2022-06-300001541157aktx:AspireCapitalFundLLCMember2020-06-012020-06-3000015411572022-04-012022-06-3000015411572021-04-012021-06-300001541157aktx:AspireCapitalFundLLCMember2021-12-310001541157aktx:AspireCapitalFundLLCMemberdei:AdrMember2020-06-3000015411572020-06-3000015411572021-01-012021-06-300001541157aktx:AspireCapitalFundLLCMemberaktx:TwoThousandAndTwentyPurchaseAgreementMember2020-06-300001541157us-gaap:PrivatePlacementMember2022-01-012022-06-300001541157aktx:March2022PlacementAgentWarrantsMember2022-01-012022-06-300001541157aktx:March2022InvestorWarrantsMember2022-01-012022-06-300001541157aktx:December2021PlacementAgentWarrantsMember2022-01-012022-06-300001541157aktx:December2021InvestorWarrantsMember2022-01-012022-06-300001541157aktx:July2021PlacementAgentWarrantsMember2021-01-012021-12-3100015411572021-01-012021-12-3100015411572022-06-3000015411572021-12-31iso4217:USDxbrli:sharesxbrli:pureiso4217:USDxbrli:sharesaktx:Daktx:item
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
September 2022
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant’s name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
CONTENTS
On September 27, 2022, Akari Therapeutics, Plc (the “Company”) issued unaudited interim condensed consolidated financial statements as of June 30, 2022, prepared in accordance with generally accepted accounting principles in the United States, together with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operations for the same period. Attached hereto and incorporated by reference herein are the following exhibits:
99.1 | | Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2022 |
| | |
99.2 | | Management Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2022 |
In addition, on September 27, 2022, the Company issued a press release announcing its second quarter and first half 2022 financial results and recent clinical progress highlights. A copy of the press release is attached hereto as Exhibit 99.3, and incorporated herein by reference.
The information contained in Exhibits 99.1 and 99.2 and the statements under “Second Quarter 2022 Financial Results”, the accompanying financial statements and “Cautionary Note Regarding Forward-Looking Statements” of Exhibit 99.3 are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Akari Therapeutics, Plc |
| (Registrant) |
| |
| By: | /s/ Rachelle Jacques |
| Name: | Rachelle Jacques |
| Title: | President and Chief Executive Officer |
| |
Date: September 27, 2022 | |
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
